CP
SMED

Castleview Partners’s Sharps Compliance Corp SMED Stock Holding History

Castleview Partners’s Portfolio SMED Stock Details SMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$3K Buy
+252
New +$3.51K ﹤0.01% 850

Other funds holding SMED

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Castleview Partners's SMED Position: Q2 2021 in Review

Castleview Partners opened a new position in Sharps Compliance Corp (SMED) in Q2 2021: 252 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #850 among its holdings.

83 funds tracked by Wall St. Rank hold SMED as of Q2 2021.

  • Castleview Partners held 252 shares of Sharps Compliance Corp worth $3K as of Q2 2021.
  • Sharps Compliance Corp was a new Castleview Partners position in Q2 2021.
  • Sharps Compliance Corp made up ﹤0.01% of Castleview Partners's portfolio in Q2 2021, its #850 holding.
  • 83 funds tracked by Wall St. Rank held Sharps Compliance Corp as of Q2 2021.

Based on Castleview Partners's 13F filing for Q2 2021, filed 17 Aug 2021.